From: Head and neck cutaneous melanoma: 5-year survival analysis in a Serbian university center
Number | Mean age (years) | Std. deviation | |
Gender | |||
Male | 67 | 61.78 | 13.62 |
Female | 49 | 61.45 | 14.35 |
Gender | |||
Male | Female | Total | |
Age | |||
< 30 | 1 | 2 | 3 |
31–40 | 4 | 2 | 6 |
41–50 | 10 | 7 | 17 |
51–60 | 16 | 12 | 28 |
61–70 | 14 | 11 | 25 |
71–80 | 18 | 10 | 28 |
81 + | 4 | 5 | 9 |
Total | 67 | 49 | 116 |
Male (n, %) | Female (n, %) | Total | |
Location | |||
Face | 23 (34.3%) | 27 (55.1%) | 50 (43.1%) |
Scalp | 27 (40.3%) | 5 (10.2%) | 32 (27.6%) |
Ear | 6 (9,0%) | 5 (10,2%) | 11 (9,5%) |
Neck | 11 (16.4%) | 12 (24.5%) | 23 (19.8%) |
Total | 67 (100.0%) | 49 (100.0%) | 116 (100.0%) |
Male | Female | Total | |
Stage | |||
IA | 6 (8.96%) | 11(22.45%) | 17 (14.66%) |
IB | 17 (25.37%) | 11(22.45%) | 28 (24.14%) |
IIA | 13 (19.40%) | 9(18.37%) | 22 (18.97%) |
IIB | 4 (5.97%) | 3 (6.12%) | 7 (6.03%) |
IIC | 4 (5.97%) | 5 (10.20%) | 9 (7.76%) |
III | 14 (20.90%) | 8 (16.33%) | 22 (18.97%) |
IV | 9 (13.43%) | 2 (4.08%) | 11 (9.48%) |
Total | 67 (100.00%) | 49 (100.00%) | 116 (100.00%) |